Addex appoints Graham Dixon CSO
This article was originally published in Scrip
Addex Therapeutics, a company pioneering allosteric modulation-based oral small molecule drug discovery and development, has made Dr Graham Dixon its first chief scientific officer and head of research. Dr Dixon, who has over 20 years' experience in pharmaceutical research, will report to Dr Bharat Chowrira, CEO of Addex. Dr Dixon most recently served as CSO at Galapagos.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.